Target intelligence / Profile preview

Elongin A3 family member B pseudogene (ELOA3BP)

Target
ELOA3BP
Molecular classification
Other — pseudogene, Transcription factor (ancestral/family member only: ELOA, ELOA3)
01

Overview

Elongin A3 family member B pseudogene (ELOA3BP, ELOA3P) is a non-coding pseudogene associated structurally with the Elongin A3 gene cluster, a group of primate-specific retrogenes encoding transcription elongation factors related to Elongin A. Unlike the functional ELOA3 protein, which acts as a promoter-associated pause-release factor regulating RNA polymerase II elongation, ELOA3BP does **not encode a functional protein** and is not considered a therapeutic target or direct disease gene. The region is referenced in genomic association studies for certain diseases, but there is no evidence for direct causality or pharmacological relevance. Multiple aliases mix functional and non-functional members of the gene family, but for ELOA3BP itself, the correct designation is as a pseudogene without biological or medical activity[1][3].

Other names
HsT828ELOA3ELOA3BELOA3CPELOA3L1EloA3CElongin-A3TCEB3CTCEB3CLTCEB3L2eloA3-like-1Putative elongin-A3 member CRNA polymerase II transcription factor SIII subunit A3RNA polymerase II transcription factor SIII subunit A3-like-1Transcription elongation factor B polypeptide 3Celongin A3 like 1elongin-A3 member Btranscription elongation factor B polypeptide 3C-like-1transcription elongation factor B subunit 3C like[1][3]
02

Mechanism of action

null — No mechanism of action applies. For the functional ELOA3 protein, it mediates promoter-associated RNA polymerase II pause release, but the pseudogene does not encode a protein[3].

03

Biological functions

null — As a pseudogene, ELOA3BP does not encode a functional protein and lacks direct biological activityTranscription elongation (only for ELOA3, not true for ELOA3BP)
04

Disease associations

null — No validated disease association for ELOA3BP.Note: ELOA3P/ELOA3BP has been genomically associated with Tinea Capitis and Dyggve-Melchior-Clausen disease, but no direct mechanistic role is established
05

Safety considerations

null — No safety concerns or therapeutic challenges reported.
06

Interacting drugs

null — No known drugs interact with this pseudogene.

1 more in the full profile.

Beyond the preview

Go deeper on Elongin A3 family member B pseudogene (ELOA3BP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elongin A3 family member B pseudogene (ELOA3BP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call